7 enrolling by invitation. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Enrolling by invitation 7 |
| Phase 2 | 2 | Enrolling by invitation 2 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. CD19/22 CAR-T cells - Acute Lymphobkastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Enrolling by invitation | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 17 | 2026-10-10 | 2026-10-16 |
| A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies HY035 cell injection - Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 13 | 2026-08-15 | 2026-08-25 |
| PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis [18F]Fluselenamyl (FSA) - Cardiac Amyloidosis | Phase 1 | Enrolling by invitation | Washington University School of Medicine | 50 | 2026-01-14 | 2026-08-18 |
| Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma anti-CD19 CAR-NK cells - Refractory/Recurrent Central Nervous System Lymphoma | Phase 1 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 42 | 2025-03-01 | 2025-08-15 |
| A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring JNJ-75348780, JNJ-67856633, JNJ-54179060 - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Enrolling by invitation | Janssen Research & Development, LLC | 120 | 2024-12-30 | 2026-09-25 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Recurrence (2) · Agammaglobulinemia (1) · Amyloid Neuropathies, Familial (1) · Immunoglobulin Light-chain Amyloidosis (1) · Immunologic Deficiency Syndromes (1) · Leukemia (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1)
Immune System Diseases (7) · Hemic and Lymphatic Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Neoplasms by Histologic Type (6) · Lymphoma (5) · Neoplasms (5) · Hematologic Diseases (4) · Lymphoma, Non-Hodgkin (4) · Disease Attributes (3) · Leukemia, Lymphoid (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Chronic Disease (2)
Busulfan (1) · Cyclophosphamide (1) · Fibroblast Growth Factor 7 (1) · Filgrastim (1) · JNJ-64264681 (1) · JNJ-64619178 (1) · fludarabine (1) · ibrutinib (1) · plerixafor (1)
Institute of Hematology & Blood Diseases Hospital, China (1) · Janssen Research & Development, LLC (1) · Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University of Maryland, Baltimore (1) · Washington University School of Medicine (1)
United States (3) · China (2) · Australia (1) · Belarus (1) · Belgium (1) · Denmark (1) · France (1) · Georgia (1) · Greece (1) · Israel (1) · Japan (1) · Moldova (1) · Poland (1) · South Korea (1) · Spain (1)
Djordje Atanackovic, MD (1) · Suk S De Ravin, M.D. (1)